Skip to main content
Kexing Biopharm logo

Kexing Biopharm — Investor Relations & Filings

Ticker · 688136 ISIN · CNE100006ZG6 LEI · 529900Z34Q1M9A907771 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 754 across all filing types
Latest filing 2024-05-24 Declaration of Voting R…
Country CN China
Listing Shanghai Stock Exchange 688136

About Kexing Biopharm

https://www.kexingbiopharm.com/

Kexing Biopharm is an innovative biopharmaceutical enterprise engaged in the research, development, production, and sales of recombinant protein drugs and micro-ecological preparations. The company focuses on developing treatments for therapeutic areas including kidney diseases, oncology, antiviral therapy, autoimmune disorders, metabolic diseases, and degenerative diseases. A key product in its portfolio is Erythropoietin Injection. Kexing Biopharm maintains a comprehensive quality system that aligns with international standards, covering the entire drug lifecycle from production and quality control to release and transportation, ensuring the continuous and stable manufacturing of safe and effective medicines.

Recent filings

Filing Released Lang Actions
北京市嘉源律师事务所关于科兴生物制药股份有限公司2023年年度股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the 2023 Annual General Meeting (AGM) of a company. It details the procedures for convening and holding the AGM, the qualifications of attendees, the voting procedures, and the results of the shareholder votes on various resolutions. It explicitly states it is a legal opinion on the AGM process and voting results, not the AGM materials themselves or the voting results announcement alone. The document is about the AGM and its legal compliance, not the full AGM materials or the voting results announcement separately. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it includes official confirmation of the voting results and legality of the AGM proceedings. The document length is under 5,000 characters, but it contains substantive content beyond a mere announcement or report publication. Hence, it is not an RPA or RNS. The document is not an Annual Report, nor a Proxy Solicitation, nor a Management Report. It is a legal opinion on the AGM and voting results, which aligns with DVA.
2024-05-24 Chinese
第二届监事会第十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 科兴生物制药股份有限公司 regarding approval of a 2024 restricted stock incentive plan and related matters. It includes voting results and mentions that the proposals will be submitted to the shareholders' meeting for approval. The document is a formal announcement of board meeting decisions rather than a full report or financial statement. It does not contain financial data or detailed report content but rather the outcomes of a board meeting. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by company boards or senior management bodies. The document length is short (1697 characters), and it is not a report publication announcement or regulatory filing. Therefore, the best classification is MANG with high confidence.
2024-05-24 Chinese
2024年限制性股票激励计划（草案）摘要公告
Remuneration Information Classification · 95% confidence The document is a detailed announcement regarding a 2024 restricted stock incentive plan (股权激励计划) for a company named 科兴生物制药股份有限公司. It includes comprehensive information about the stock incentive plan's purpose, scope, number of shares, eligibility, conditions, pricing, vesting schedule, performance criteria, legal compliance, and procedural steps for implementation and adjustments. The document is regulatory in nature, disclosing a corporate governance and compensation-related plan to shareholders and the public. It is not a financial report, earnings release, or audit report. It is not a proxy solicitation or voting results announcement, but rather a formal disclosure of a stock-based incentive plan. This type of document fits best under the category of Remuneration Information (DEF 14A), which covers reports detailing compensation plans for executives and directors, including stock incentive plans. The document length and detail confirm it is the plan disclosure itself, not a brief announcement or summary. Therefore, the classification is DEF 14A with high confidence.
2024-05-24 Chinese
2023年年度股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a "2023 Annual General Meeting Resolution Announcement" for 科兴生物制药股份有限公司. It details the date and location of the AGM, attendance of shareholders and board members, and the voting results on various proposals including the 2023 annual report, board and supervisory reports, financial statements, profit distribution, remuneration standards, and amendments to company bylaws. The document also includes legal witness statements confirming the validity of the meeting and voting process. The content is focused on the official announcement of the voting results and resolutions passed at the AGM, rather than the full annual report or financial statements themselves. The document length is about 5220 characters, which is consistent with a detailed announcement of voting results rather than a full report. Therefore, this document fits best into the category of "Declaration of Voting Results & Voting Rights Announcements (DVA)".
2024-05-24 Chinese
关于独立董事公开征集委托投票权的公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a public announcement by the company regarding the solicitation of proxy voting rights by an independent director for a specific upcoming shareholders' meeting. It details the voting period, the agenda items to be voted on, the procedures for submitting proxy votes, and includes an authorization form for shareholders to delegate their voting rights. The content focuses on the process of collecting proxy votes for the 2024 second extraordinary general meeting, specifically related to a restricted stock incentive plan. There are no financial statements, earnings data, or management discussion of results. The document is not a report itself but an announcement related to shareholder voting and proxy solicitation. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length is under 5,000 characters, but it contains detailed proxy solicitation information rather than just a brief report publication announcement or regulatory filing. Hence, the classification is PSI with high confidence.
2024-05-24 Chinese
上海荣正企业咨询服务（集团）股份有限公司关于科兴生物制药股份有限公司2024年限制性股票激励计划（草案）之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is an Independent Financial Advisor Report regarding a 2024 Restricted Stock Incentive Plan for a listed company (科兴生物制药股份有限公司). It contains detailed analysis and opinions on the stock incentive plan, including legal compliance, feasibility, scope of incentive recipients, pricing, and conditions. The document is lengthy (15,000 characters) and includes substantive financial and legal content related to the incentive plan. It is not a simple announcement or a brief summary but a detailed advisory report. This type of document fits the category of Audit Report / Information (AR), as it is a standalone advisory report on a specific financial plan, not a full annual or interim report, nor a regulatory filing or announcement. Therefore, the correct classification is AR with high confidence.
2024-05-24 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.